SCHEMBL6018089

SCHEMBL6018089

COc1ccccc1-c1nc(C(=O)NCc2ccc(C)c(Cl)c2)c(O)c(=O)n1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
MAPT P10636 4/20 0.44
HPGD P15428 4/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 2/20 0.44
WDR5 P61964 1/20 0.43
TACR1 P25103 1/20 0.42
NPSR1 Q6W5P4 3/20 0.41
HTT P42858 2/20 0.41
ALOX12 P18054 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KCNE1 P15382 1/20 0.41
CCR1 P32246 1/20 0.41
KCNQ1 P51787 1/20 0.41
LMNA P02545 4/20 0.41
GAA P10253 1/20 0.41
ABCB1 P08183 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017876 0.94 WDR5 (0.49) TSHRMAPTHPGDALDH1A1KDM4E
SCHEMBL6018060 0.92 TSHR (0.47) TSHRMAPTHPGDALDH1A1KDM4E
SCHEMBL6017926 0.90 TSHR (0.44) TSHRMAPTHPGDALDH1A1WDR5
SCHEMBL6017632 0.86 KCNE1 (0.54) TSHRMAPTALDH1A1KDM4ENPSR1
SCHEMBL6017692 0.86 MMP1 (0.47) ALDH1A1WDR5ABCB1CNR1CNR2
SCHEMBL6017747 0.86 CNR1 (0.40) WDR5KCNE1CCR1KCNQ1CNR1
SCHEMBL6017677 0.84 LMNA (0.48) TSHRHPGDWDR5KCNE1CCR1
SCHEMBL6017757 0.83 KMT2A (0.39) TSHRMAPTALDH1A1WDR5NPSR1
SCHEMBL6017888 0.83 MAPT (0.41) MAPTALDH1A1KDM4ELMNAGAA
SCHEMBL6017750 0.82 KDM4E (0.45) HPGDALDH1A1KDM4EHSD17B10WDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US claimed
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed
WO-2004096128-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS TSHR 4295/4885MAPT 2576/4885HPGD 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.